| [1] |
GUO Ye, ZHANG Chenping.
Expert consensus on immune checkpoint inhibitors treatment for recurrent/metastatic head and neck squamous cell carcinoma (2024 edition)
[J]. China Oncology, 2024, 34(4): 425-438.
|
| [2] |
HU Xiaoyu, CAI Yuwen, YE Fugui, SHAO Zhimin, HU Weigang, YU Keda.
Impact of BRCA1/2 germline mutation on the incidence of second primary cancer following postoperative radiotherapy in patients with triple-negative breast cancer
[J]. China Oncology, 2024, 34(2): 185-190.
|
| [3] |
LIU Zhiyu, XU Dong, CHEN Xihao, LI Jipeng.
Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer
[J]. China Oncology, 2024, 34(2): 191-200.
|
| [4] |
CHEN Hongyu, SU Pengyu, LUO Wenzi, PANG Dequan, WANG Feiran.
A study of relationship between cardiac exposure dose-volume and cardiovascular autonomic dysfunction in radiotherapy
[J]. China Oncology, 2024, 34(11): 1036-1044.
|
| [5] |
CUI Jianchun, LU Wei, LI Qianyong.
Clinical application value of surface-guided automatic positioning in pelvic tumor radiotherapy
[J]. China Oncology, 2024, 34(10): 966-971.
|
| [6] |
WANG Yan, SU Yue, HU Tu, LIU Qiying, YAO Weiqiang, CHEN Yong, YAN Wangjun, ZHANG Zhen.
Retrospective analysis of short-term efficacy and safety of preoperative radiotherapy for 33 cases of locally high-risk soft tissue sarcoma
[J]. China Oncology, 2023, 33(7): 693-700.
|
| [7] |
BI Zhao, WANG Yongsheng.
New concept of de-escalation management strategy in breast cancer patients with 1-2 positive sentinel lymph nodes
[J]. China Oncology, 2023, 33(6): 560-565.
|
| [8] |
HUANG He, JU Houyu, YANG Wenyi, YAN Ming, REN Guoxin, HU Jingzhou.
Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy
[J]. China Oncology, 2023, 33(6): 613-618.
|
| [9] |
ZHANG Shaoqiu, YAN Li, LI Ruichen, ZHAO Yang, WANG Xiaoshen, YANG Xuguang, ZHU Yi.
Recent advances and prospect in immune microenvironment and its mechanisms of function in head and neck squamous cell carcinoma
[J]. China Oncology, 2023, 33(6): 629-636.
|
| [10] |
DONG Xiaohuan, LIU Jun, LI Hongxuan, CHENG Yan, LI Yue, YU Wen, CAI Xuwei, FU Xiaolong.
Preliminary study on involving field irradiation radiotherapy in neoadjuvant chemoradiotherapy for esophageal cancer
[J]. China Oncology, 2023, 33(3): 267-273.
|
| [11] |
TANG Tianci, ZHAI Zhoushijia, LI Shengwei, WANG Xiaoshen, NI Xiaochen.
Application of generalized equivalent uniform dose optimization in the treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy
[J]. China Oncology, 2023, 33(3): 274-281.
|
| [12] |
WANG Yu, BI Nan.
Advancements in the research of immunomodulatory effects of radiation therapy: from basic to clinical
[J]. China Oncology, 2023, 33(12): 1083-1091.
|
| [13] |
ZHUANG Han, LING Chifang, WANG Jiazhou, HAN Xu, JIANG Rui, HU Weigang.
Radiation therapy in locally advanced pancreatic cancer with 75 Gy simultaneous integrated boost: a dosimetric feasibility study
[J]. China Oncology, 2023, 33(1): 54-60.
|
| [14] |
XU Tingting, HU Chaosu, LI Baosheng.
Clinical consensus on the treatment of locally advanced squamous cell carcinoma of the head and neck with anti-EGFR monoclonal antibody (2023 edition)
[J]. China Oncology, 2023, 33(1): 81-94.
|
| [15] |
CAI Gang, WANG Shubei, CHEN Jiayi.
The current data and challenge of radiotherapy in the case management of gastric cancer
[J]. China Oncology, 2022, 32(7): 581-587.
|
